期刊名：Hematology Reports

期刊主页：https://www.mdpi.com/journal/hematolrep

多发性骨髓瘤（Multiple Myeloma, MM）是血液系统恶性肿瘤的重要类型之一。近年来，随着靶向治疗、免疫治疗及精准医学的发展，多发性骨髓瘤的诊疗策略不断更新，新型治疗方案、真实世界研究及疾病机制探索成为该领域的重要研究方向。

本期文献清单精选 MDPI Hematology Reports 中近期发表的多发性骨髓瘤相关研究，涵盖新型治疗策略、临床结局评估、疾病机制探索及患者管理等方向，旨在为科研人员和临床工作者提供该领域近期研究进展参考。

1. Teclistamab Monotherapy in Relapsed or Refractory Multiple Myeloma: A Real-World Focused Systematic Review and Meta-Analysis of Efficacy and Safety

Teclistamab单药治疗复发或难治性多发性骨髓瘤：基于真实世界研究的疗效与安全性系统综述和Meta分析

https://doi.org/10.3390/hematolrep18040054

2. Role of Daratumumab, Lenalidomide, and Dexamethasone in Transplantation-Eligible Patients with Multiple Myeloma After the Failure of Bortezomib-Based Induction Therapy

Daratumumab、来那度胺联合地塞米松在硼替佐米诱导治疗失败后适合移植多发性骨髓瘤患者中的应用价值

https://doi.org/10.3390/hematolrep17060057

3. Efficacy of Anti-CD38 Monoclonal Antibodies for Relapsed or Refractory Multiple Myeloma in Stem Cell Transplant-Ineligible Patients Aged over 65 Years: A Propensity Score-Matched Study

抗CD38单克隆抗体治疗65岁以上不适合干细胞移植的复发或难治性多发性骨髓瘤患者的疗效：倾向评分匹配研究

https://doi.org/10.3390/hematolrep16040068

4. The Real-World Outcomes of Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab, Pomalidomide, and Dexamethasone

Elotuzumab、泊马度胺和地塞米松治疗复发/难治性多发性骨髓瘤的真实世界结局分析

https://doi.org/10.3390/hematolrep16040058

5. The Gut Microbiome Role in Multiple Myeloma: Emerging Insights and Therapeutic Opportunities

肠道微生物组在多发性骨髓瘤中的作用：新兴认识与治疗机遇

https://doi.org/10.3390/hematolrep17060056

6. Therapeutic Potential of Exportin 1 and Aurora Kinase A Inhibition in Multiple Myeloma Cells

抑制Exportin 1和Aurora激酶A在多发性骨髓瘤细胞中的治疗潜力

https://doi.org/10.3390/hematolrep18010010

7. Prevalence, Outcomes and Impact of Disease-Related Complications in the Survival of Multiple Myeloma Patients

多发性骨髓瘤疾病相关并发症的发生率、临床结局及其对患者生存的影响

https://doi.org/10.3390/hematolrep16010009

8. Digital Symptom Reporting for Treatment Readiness Before Daratumumab: A Blinded Prospective Study in Multiple Myeloma

Daratumumab治疗前准备阶段的数字化症状报告：一项多发性骨髓瘤患者盲法前瞻性研究

https://doi.org/10.3390/hematolrep18030041

9. Identifying Candidates for Effective Utilization of Stored Autologous PBSCs in Salvage Transplantation for Multiple Myeloma: Who Benefits Most?

识别适合利用储存自体外周血干细胞进行挽救性移植的多发性骨髓瘤患者：谁能获益最大？

https://doi.org/10.3390/hematolrep16030046

10. Tympanic Membrane Involvement of Multiple Myeloma: Report of a Case

多发性骨髓瘤累及鼓膜：病例报告

https://doi.org/10.3390/hematolrep18040055

Hematology Reports 期刊介绍

主编：Prof. Dr. Claudio Cerchione

Hematology Reports （ISSN 2038-8330）创刊于2009年，是一个国际性、经同行评审的开放获取期刊。期刊涵盖血液疾病的预防、诊断与治疗，以及相关的分子与细胞生物学、遗传学、病理生理学、流行病学和临床对照试验等领域。目前期刊已被Scopus、ESCI (Web of Science)、 PMC、 PubMed、 Embase等多个数据库收录。

2025 Impact Factor：1.9

2025 CiteScore：2.4

Time to First Decision：26.3 Days

Acceptance to Publication：4.6 Days